Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous infliximab with or without concomitant immunosuppression in Crohn's disease
NL-OMON59580Phase 4Completed
- Sponsor
- Amsterdam University Medical Center
- Start
- Nov 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4 trial of infliximab in Crohn's disease (2 arms), sponsored by Amsterdam University Medical Center. Started Nov 2021; status: completed.
02
Drugs
infliximab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NL-OMON59580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59580.